Archives of otolaryngology--head & neck surgery · 2003
Significance of c-Myc and Bcl-2 protein expression in nasopharyngeal carcinoma.
СтатьяВалидационное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yu Yongqiang, Dong Weidong, Li Xin, Yu Enju, Zhou Xiaorong, Li Shuhua
Аннотация
OBJECTIVE: To investigate the relationship between oncogene protein expression and nasopharyngeal carcinoma outcome.
DESIGN: Tumor samples from 51 patients with nasopharyngeal carcinoma were analyzed by immunohistochemical staining for expression of Bcl-2 and c-Myc protein before irradiation. Five-year follow-up data were available.
RESULTS: Thirty-one (61%) of 51 tumors expressed Bcl-2 protein, and 29 (57%) of 51 tumors expressed c-Myc protein. In the Bcl-2+ group, 20 (65%) and 19 (61%) of 31 patients experienced recurrence or died, respectively, whereas only 7 (35%) and 5 (25%) of 20 patients with Bcl-2- tumors did so. On the other hand, patients with c-Myc+ tumors had lower recurrence and death rates (38% [11/29] and 34% [10/29], respectively) than those with c-Myc- tumors (73% [16/22] and 64% [14/22], respectively). A statistically significant association was confirmed between Bcl-2 and c-Myc positivity and patient outcome.
CONCLUSION: Expression of Bcl-2 and c-Myc protein seems to be a useful marker to reflect irradiation response and to predict illness condition and patient outcome.
DESIGN: Tumor samples from 51 patients with nasopharyngeal carcinoma were analyzed by immunohistochemical staining for expression of Bcl-2 and c-Myc protein before irradiation. Five-year follow-up data were available.
RESULTS: Thirty-one (61%) of 51 tumors expressed Bcl-2 protein, and 29 (57%) of 51 tumors expressed c-Myc protein. In the Bcl-2+ group, 20 (65%) and 19 (61%) of 31 patients experienced recurrence or died, respectively, whereas only 7 (35%) and 5 (25%) of 20 patients with Bcl-2- tumors did so. On the other hand, patients with c-Myc+ tumors had lower recurrence and death rates (38% [11/29] and 34% [10/29], respectively) than those with c-Myc- tumors (73% [16/22] and 64% [14/22], respectively). A statistically significant association was confirmed between Bcl-2 and c-Myc positivity and patient outcome.
CONCLUSION: Expression of Bcl-2 and c-Myc protein seems to be a useful marker to reflect irradiation response and to predict illness condition and patient outcome.
Предметные рубрики MeSH
Biomarkers, TumorCarcinoma, Squamous CellFemaleFollow-Up StudiesGene AmplificationGene Expression Regulation, NeoplasticHumansImmunohistochemistryMaleMiddle AgedMultivariate AnalysisNasopharyngeal NeoplasmsNeoplasm Recurrence, LocalNeoplasm StagingPredictive Value of TestsPrognosisProportional Hazards ModelsProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-mycSurvival AnalysisTreatment Outcome